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It has been proposed that reactive oxygen species, and
in particular H2O2, may be involved in the activation of
NF-kB by diverse stimuli in different cell types. Here we
have investigated the effect of a range of putative anti-
oxidants on NF-kB activation by interleukin-1 and tu-
mor necrosis factor as well as the ability of H2O2 to
activate NF-kB in primary human umbilical vein endo-
thelial cells and the transformed human endothelial cell
line ECV304. Activation of NF-kB and stimulation of
IkBa degradation by H2O2 was only evident in the trans-
formed cells and required much longer contact times
than that observed with interleukin-1 or tumor necrosis
factor. Furthermore, only H2O2 was sensitive to N-
acetyl-L-cysteine, and no increase in H2O2 was detected
in response to either cytokine. Pyrrolidine dithiocar-
bamate has been purported to be a specific antioxidant
inhibitor of NF-kB that acts independently of activating
agent or cell type. However, we found that tumor necro-
sis factor- but not interleukin-1-driven NF-kB activation
and IkBa degradation were sensitive to pyrrolidine di-
thiocarbamate in transformed cells, while neither path-
way was inhibited in primary cells. Phorbol ester-medi-
ated activation was sensitive in both transformed and
primary cells. Other antioxidants failed to inhibit either
cytokine, while the iron chelators desferrioxamine and
2,2,6,6-tetramethylpiperidine-1-oxyl mimicked the pat-
tern of inhibition seen for the dithiocarbamate. This
suggested that pyrrolidine dithiocarbamate was inhib-
iting NF-kB activation in endothelial cells primarily
through its iron-chelating properties. Tumor necrosis
factor, but not interleukin-1, was found to induce lipid
peroxidation in ECV304 cells. This was inhibited by pyr-
rolidine dithiocarbamate and desferrioxamine. t-Butyl
hydroperoxide, which induces lipid peroxidation, acti-
vated NF-kB. Finally, butylated hydroxyanisole, which
inhibits lipid peroxidation but has no iron-chelating
properties, inhibited NF-kB activation by tumor necro-
sis factor but not interleukin-1.
Taken together, the results argue against a role for
H2O2 in NF-kB activation by cytokines in endothelial
cells. Furthermore, tumor necrosis factor and interleu-
kin-1 activate NF-kB through different mechanisms in
ECV304 cells, with the tumor necrosis factor pathway
involving iron-catalyzed lipid peroxidation.
The inducible, higher eukaryotic transcription factor NF-kB
has an important role in the regulation of a number of genes
involved in immune and inflammatory responses. It is acti-
vated in many cell types by a wide range of stimuli including
the proinflammatory cytokines interleukin-1 (IL-1)1 and tumor
necrosis factor (TNF) and the protein kinase C activator phor-
bol 12-myristate 13-acetate (PMA) (reviewed in Ref. 1).
In endothelial cells (ECs), activation of NF-kB is central to
the regulation of many genes by IL-1 and TNF such as the cell
adhesion molecules vascular cell adhesion molecule-1, intercel-
lular adhesion molecule-1, and E-selectin (2) and tissue factor
(3). Recently, NF-kB has been identified in an activated form in
the ECs of atherosclerotic plaques (4), and it has been sug-
gested that NF-kB may play a central role in the initiation of
atherosclerosis (5).
NF-kB exists in a latent form in the cytoplasm of unstimu-
lated cells comprising a transcriptionally active dimer bound to
an inhibitor protein, IkB. The currently known subunit mem-
bers of the NF-kB family in mammals are p50, RelA (p65),
c-Rel, p52, and RelB, while multiple forms of IkB also exist,
namely IkBa, b, g, and Bcl-3 (reviewed in Ref. 6). The predom-
inant form of NF-kB activated in cells is a p50/RelA het-
erodimer, which is associated with IkBa in resting cells. Upon
stimulation with agents such as IL-1 and TNF, IkBa is rapidly
phosphorylated on two serine residues (Ser32 and Ser36), which
targets the inhibitor protein for ubiquitination and subsequent
degradation by the 26 S proteasome (reviewed in Ref. 7). This
allows NF-kB to translocate to the nucleus and activate target
genes by binding with high affinity to kB elements in their
promoters. The phosphorylation and degradation of IkBa are
tightly coupled events (7). Thus, it is likely that agents that
activate NF-kB do so through the activation of a specific IkBa
kinase or, alternatively, by inactivating a particular phospha-
tase. A high molecular mass kinase complex that phosphoryl-
ates IkBa on Ser32 and Ser36 has been identified (8).
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The upstream events that lead to phosphorylation of IkBa
are unclear. A model has been proposed whereby diverse
agents all activate NF-kB by causing oxidative stress (an in-
crease in intracellular reactive oxygen intermediates (ROS))
(9). In particular, H2O2 has been implicated as a common
second messenger in the various pathways leading to NF-kB
activation (10). This hypothesis is based on several of lines of
evidence. First, in some cell types H2O2 has been shown to be
released in response to agents that also activate NF-kB (9–11).
Second, direct addition of H2O2 to culture medium has been
shown to activate NF-kB in some cell lines (12, 13). Third,
overexpression of the H2O2-metabolizing enzyme catalase in a
mouse epidermal cell line was shown to attenuate the activa-
tion of NF-kB by TNF and okadaic acid, while overexpression of
the H2O2-producing enzyme superoxide dismutase potentiated
the activation, suggesting a role for H2O2 in these pathways to
NF-kB (10). Other work has suggested that some of these
observations are cell-specific. H2O2 had no stimulatory effect
on NF-kB in a number of other cell types (14–17), while Suzuki
et al. (18) showed that in COS-1 cells, overexpression of cata-
lase did not block activation of NF-kB by either TNF or PMA.
It has also been suggested that oxidative stress facilitates but
does not mediate NF-kB activation (14).
Another line of evidence implicating oxidative stress and
H2O2 as central to NF-kB activation has been the effect of
antioxidants in inhibiting NF-kB activation in response to di-
verse stimuli. Two compounds in particular have been exten-
sively used, the glutathione precursor and radical scavenger
N-acetyl-L-cysteine (NAC) and the putative antioxidant pyrrol-
idine dithiocarbamate (PDTC). However, the effect of NAC on
NF-kB is also somewhat cell-specific, in that although it has
proved inhibitory in some cells (12, 13), we and others have
reported NAC-insensitive pathways to NF-kB (16, 17, 19).
PDTC seems to be a better general inhibitor of NF-kB and, in
fact, has been proposed as a specific universal inhibitor of
NF-kB that acts independently of the activating agent and cell
type used (9). However, in addition to its radical scavenging
and metal-chelating properties (9, 20), PDTC can also exert a
pro-oxidant effect in some cells by increasing oxidized glutathi-
one levels (21, 22), which also leads to an inhibition of NF-kB
(22, 23).
Information on the role of oxidative stress and H2O2 in
cytokine stimulation of NF-kB in ECs remains limited, mainly
coming from studies using PDTC or NAC to perturb particular
genes downstream of NF-kB activation (24–26). Given the im-
portance of NF-kB in ECs together with the often cell-specific
nature of the effect of H2O2 and antioxidants on NF-kB activa-
tion, we decided to investigate the role of H2O2 and oxidative
stress in NF-kB activation in ECs using both primary and
transformed ECs. Our results show that although H2O2 acti-
vates NF-kB in transformed ECs, it is unlikely to have a role in
the cytokine-mediated pathways to NF-kB in transformed or
primary ECs. In transformed cells, TNF but not IL-1 was
sensitive to PDTC, while in primary cells neither stimulus was
inhibited. Further, we show that the ability of PDTC to inhibit
NF-kB activation by TNF in transformed ECs involves inhibi-
tion of iron-catalyzed lipid peroxidation that is not important
for activation of NF-kB by IL-1.
EXPERIMENTAL PROCEDURES
Materials—The immortalized human endothelial cell line ECV304
(27) and human Jurkat T cells were obtained from the European Col-
lection of Animal Cell Cultures (Salisbury, United Kingdom). Pooled
human umbilical vein endothelial cells (HUVECs) were obtained at
first passage from Clonetics Corporation (San Diego, CA). RPMI 1640
medium, heat-inactivated fetal bovine serum (FBS), trypsin-EDTA, and
penicillin-streptomycin-glutamine were from Life Technologies, Inc.
(Paisley, Scotland). Human recombinant IL-1a was a gift from NCI,
National Institutes of Health (Frederick, MD), while human recombi-
nant TNFa was a gift from Dr. Steve Foster (Zeneca Pharmaceuticals,
Macclesfield, UK). The 22-base pair oligonucleotide, 59-AGT TGA GGG
GAC TTT CCC AGG C-39, containing the NF-kB consensus sequence
(underlined), T4 polynucleotide kinase, and the Cytotox 96TM nonradio-
active cytotoxicity assay were from Promega Corp. (Madison, WI). The
22-base pair oligonucleotide, 59-AGT TGA GGC GAC TTT CCC AGG
C-39, containing the mutated NF-kB consensus sequence (underlined),
the rabbit polyclonal antibody to human IkBa, and the antisera to the
NF-kB subunits p50 and c-Rel were from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA). Antiserum to the NF-kB subunit RelA (p65) was a
gift from Dr. Jean Imbert (INSERM, Marseille, France). [g-32P]ATP
(3000 Ci/mmol) and enhanced chemiluminescence (ECL) reagent were
from Amersham International (Aylesbury, UK). Poly(dIzdC) was from
Pharmacia Biosystems (Milton Keynes, UK). All other reagents, includ-
ing heparin (sodium salt), human recombinant acidic fibroblast growth
factor, medium 199 (HEPES modification), PDTC (ammonium salt),
diethyldithiocarbamate (DDTC), pyrrolidine, pyroglutamic acid, NAC,
desferrioxamine, allopurinol, the spin traps 2,2,6,6-tetramethylpiperi-
dine-1-oxyl (TEMPO), and 5,5-dimethyl-1-pyrroline N-oxide (DMPO),
FeCl3, H2O2, PMA, butylated hydroxyanisole (BHA), tert-butylhy-
droperoxide (t-BHP), thiobarbituric acid, anti-mouse IgG peroxidase
conjugate, scopoletin, horseradish peroxidase (type II), and catalase
were from Sigma (Poole, UK).
Cell Culture and Treatments—ECV304 cells were grown in medium
199 (HEPES modification) containing 10% (v/v) FBS, and passaged
when confluent using 0.05% (w/v) trypsin, 0.02% (w/v) EDTA. HUVECs
were grown in medium 199 containing 20% FBS, 10 ng/ml acidic fibro-
blast growth factor, and 90 mg/ml heparin. The medium was changed
every 48 h, and cells were passaged when 80–90% confluent using
trypsin-EDTA. Jurkat T cells were grown in RPMI 1640 medium con-
taining 10% FBS. All media were supplemented with 100 units/ml
penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine, and cells
were maintained at 37 °C in a humidified atmosphere of 5% CO2. Cells
were pretreated with the test compounds or left untreated before the
addition of IL-1, TNF, PMA, or H2O2 as described in the figure legends.
All experiments were carried out in complete medium at 37 °C. PDTC,
DDTC, and pyrrolidine were dissolved in PBS; pyroglutamic acid
(PGA), desferrioxamine (DFO), and FeCl3 were dissolved in H2O; NAC
was dissolved in 25 mM Tris-HCl, pH 7.5; BHA was dissolved in ethanol;
and PMA, allopurinol, TEMPO, and DMPO were dissolved in Me2SO.
NAC and PGA were adjusted to pH 7.4 with 1 N NaOH. None of the
vehicles had any effect on NF-kB alone at the concentrations used. No
metal spatulas were used. The effect of the compounds on cell viability
was assessed using the Cytotox 96TM nonradioactive cytotoxicity assay,
as described by the manufacturers. This system uses lactate dehydro-
genase release as an index of cell toxicity. At the concentrations used
here, NAC interfered with this assay, and thus the magnitude of release
of lactate dehydrogenase activity from NAC-treated cells was deter-
mined directly by monitoring spectrophotometrically the decrease in
absorbance at 340 nm in the presence of 75 mM Tris-HCl, pH 7.2,
containing 150 mM KCl, 0.2 mM NADH, and 4.8 mM sodium pyruvate.
Measurement of LDH release from intact cells and examination of
monolayer morphology revealed that none of the compounds used were
toxic to the cells at the exposure times and concentrations used here.
Cell Fractionation and Preparation of Nuclear Extracts—Nuclear
extracts were prepared using a modified version of the method of
Osborn et al. (28). Confluent ECV304 cells or HUVECs in six-well plates
(3-ml volume) were treated as described in the figure legends. Stimu-
lation was terminated by removal of medium followed by washing twice
with 3 ml of ice-cold PBS (0.145 M NaCl, 0.027 M phosphate buffer, pH
7.6). Washed cells were then scraped into 1 ml of hypotonic buffer (10
mM Hepes buffer, pH 7.9, containing 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride). Stimulation
of Jurkat T cells (5 3 106 in 1 ml of medium) was terminated by the
removal of cells into 5 ml of ice-cold PBS, followed by centrifugation
(170 g, 10 min). Cell pellets were resuspended in 1 ml of hypotonic
buffer. Nuclear extracts were subsequently prepared as described pre-
viously (17). Protein concentrations were determined using the method
of Bradford (29). Extracts were then stored at 220 °C and assayed for
NF-kB activity the next day.
Electrophoretic Mobility Shift Assay—Nuclear extracts (2 mg of pro-
tein) were incubated with 10,000 cpm of a 22-base pair oligonucleotide
containing the NF-kB consensus sequence that had previously been
labeled with [g-32P]ATP (10 mCi/mmol) by T4 polynucleotide kinase.
Incubations were performed for 30 min at room temperature, in the
presence of 2 mg of poly(dIzdC) as nonspecific competitor and 10 mM
Tris-HCl, pH 7.5, containing 100 mM NaCl, 1 mM EDTA, 5 mM dithio-
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threitol, 4% glycerol, and 100 mg/ml nuclease-free bovine serum albu-
min. For competition studies, unlabeled wild type or mutant NF-kB
oligonucleotides were added to the binding reaction 30 min before the
addition of the radiolabeled probe. In experiments involving antisera to
NF-kB subunits, 0.5 ml of a specific antiserum to p50, RelA, or c-Rel was
incubated with nuclear extracts for 20 min on ice prior to the binding
reaction. All incubation mixtures were subjected to electrophoresis on
native 5% (w/v) polyacrylamide gels, which were subsequently dried
and autoradiographed.
Anti-IkBa Immunoblot Analysis—Confluent ECV304 cells in six-well
plates (3-ml volume) were treated as described in the figure legends.
Treatment was terminated by washing monolayers twice with ice-cold
PBS. Cells were then scraped into 1 ml of ice-cold radioimmune precip-
itation buffer (1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate,
and 0.1% (w/v) SDS in PBS) containing 10 mg/ml phenylmethylsulfonyl
fluoride, 7 mg/ml aprotinin, and 1 mM Na3VO4. Following further dis-
ruption of cells by passage through a 21-gauge needle (5 strokes), an
additional 0.1 mg/ml phenylmethylsulfonyl fluoride was added to sam-
ples, which were then incubated on ice for 45 min. Samples were then
centrifuged at 14,000 3 g for 20 min at 4 °C, and the supernatant was
removed as cell lysate. Supernatants were assayed for protein (29).
Equal amounts of protein (2–4 mg) were resolved by SDS-polyacryl-
amide gel electrophoresis and transferred onto nitrocellulose, and IkBa
immunoblot analysis was performed as described previously (30).
Determination of H2O2—H2O2 released from ECV304 cells was meas-
ured by the horseradish peroxidase-mediated oxidation of the fluores-
cent probe scopoletin to its nonfluorescent oxidized form (31). Since
hydrogen peroxide freely diffuses across the cell membrane, measuring
extracellular release is an indication of intracellular levels. Confluent
monolayers of ECV304 cells in six-well plates (3-ml volume) were
washed twice with Hanks’ balanced salt solution to remove phenol red
and serum. Monolayers were incubated with 3 ml of assay solution
containing stimulant (IL-1 (10 ng/ml), TNF (10 ng/ml), or PMA (100
ng/ml)), sodium azide (1 mM), scopoletin (1 mM), and horseradish per-
oxidase (0.2 units/ml) in Hanks’ balanced salt solution, for 30 min at
37 °C. The supernatant was then transferred to a test tube and cooled
to room temperature, and the fluorescence was measured on a Perkin-
Elmer LS 50B fluorimeter using an excitation wavelength of 390 nm
and an emission wavelength of 460 nm. Controls included cell-free
plates with full assay mix and cells incubated in the absence of perox-
idase. The specific decrease in fluorescence due to H2O2 was assessed by
measuring scopoletin oxidation for each sample in the presence and
absence of catalase (50 units/ml). H2O2 concentration was then deter-
mined against a standard curve, using concentrations of 0.05–0.5 mM
H2O2, as determined spectrophotometrically (e240 5 43.6 M
21 cm21).
Protein concentrations of samples were determined (29) following alkali
digestion of monolayers. H2O2 release was then expressed as pmol/
min/mg of protein.
Determination of Thiobarbituric Acid-reactive Substances (TBARS)—
Lipid peroxidation was assessed by the TBARS assay, which detects
mainly malondialdehyde (MDA), an end product of the peroxidation of
polyunsaturated fatty acids and related esters. TBARS were measured
by a modification of the method of Ohkawa et al. (32). Confluent mono-
layers of ECV304 cells in 100-mm dishes were treated as described in
the figure legends and washed in PBS before undergoing three cycles of
freeze-thawing in 200 ml of water. A 20-ml aliquot was subsequently
removed for Bradford protein determination (29), and 800 ml of assay
mix (0.4% (w/v) thiobarbituric acid, 0.5% (w/v) SDS, 9.4% (v/v) acetic
acid, pH 3.5) was added to the remaining sample. Samples were incu-
bated for 60 min at 95 °C, cooled to room temperature, and centrifuged
at 14,000 3 g for 10 min, and the absorbance of the supernatants was
read at 532 nm against a standard curve prepared using the MDA
standard (10 mM 1,1,3,3-tetramethoxypropane in 20 mM Tris-HCl, pH
7.4). Results were calculated as nmol of MDA equivalents/mg of protein
and expressed as a percentage of matched control values.
Statistical Analysis—Significance was evaluated by Student’s t test.
RESULTS
Hydrogen Peroxide Activates NF-kB in ECV304 Cells but Not
HUVECs and with Different Kinetics Compared with IL-1 and
TNF—Fig. 1A shows that nuclear extracts from untreated
ECV304 cells contained trace amounts of NF-kB, the levels of
which varied slightly between experiments (lanes 1, 9, 17, and
25). Following treatment with 10 ng/ml IL-1 (lanes 2–8) or 10
ng/ml TNF (lanes 10–16), NF-kB was activated, as evidenced
by the increased retardation of the DNA probe containing the
kB motif. This activation was evident from 5 min (lanes 2 and
10) and peaked at 30 min (lanes 4 and 12). NF-kB activity was
strong for at least 4 h (lanes 6 and 14) and still detectable at
24 h (lanes 8 and 16). Treatment of cells with 100 ng/ml PMA
(lanes 18–24) gave a somewhat different time course of activa-
tion in that active NF-kB only became detectable at 30 min
(lane 20) and was greatly reduced by 24 h (lane 24). Prolonged
treatment of ECV304 cells with H2O2 led to activation of NF-
kB. When cells were treated with 0.2 mM H2O2 for 4 h, a strong
activation was observed (compare lanes 28 and 25). In contrast
to the rapid response seen for IL-1 and TNF, the H2O2-stimu-
lated activation was not detectable after 1 h (compare lanes 26
and 25) and did not peak until 4 h (lane 29). H2O2-mediated
activation was also more transient than that seen for IL-1 and
TNF, with activity greatly decreased by 8 h (compare lanes 29
and 28) and identical to control levels at 24 h (compare lanes 30
and 25). A concentration of 0.2 mM H2O2 was optimal in this
effect. Fig. 1B confirms that the protein-DNA complexes acti-
vated by IL-1, TNF, PMA, and H2O2 were all specific for NF-
kB, since 18 or 180 fmol of unlabeled NF-kB wild type consen-
sus sequence effectively competed with each binding activity,
while the same concentrations of a mutant NF-kB oligonucleo-
tide containing a single base pair change in the consensus
sequence failed to compete with binding.
Since this is the first study reporting NF-kB activation in
ECV304 cells, we also characterized the NF-kB subunits pres-
ent in the complexes activated by the four stimuli. Fig. 1C
demonstrates that IL-1, TNF, PMA, and H2O2 activated simi-
lar NF-kB complexes. Using specific antisera to p50, RelA, and
c-Rel, the same pattern of supershifting was seen for IL-1-,
TNF-, PMA-, and H2O2-activated NF-kB (lanes 1–4, 5–8, 9–12,
and 13–16, respectively). This revealed the presence of two
main NF-kB complexes. Antiserum to p50 affected both the
lower and upper complex (lanes 2, 6, 10, and 14), while RelA
antiserum only reacted with the upper complex (lanes 3, 7, 11,
and 15). There was no detectable reaction with c-Rel antiserum
(lanes 4, 8, 12, and 16). Hence, it was likely that IL-1, TNF,
PMA, and H2O2 were activating two NF-kB complexes, tenta-
tively identified as p50/p50 homodimers and p50/RelA
heterodimers.
Fig. 1D shows that IL-1, TNF, and PMA also activated
NF-kB in HUVECs as has been well characterized by others
(2). IL-1 (10 ng/ml) gave a similar time course of activation of
NF-kB to that seen in ECV304 cells, with activity detectable
after 5 min (compare lanes 2 and 1), maximal at 1 h (lane 5) and
still apparent at 24 h (lane 8). Activation of NF-kB by TNF (10
ng/ml) and PMA (100 ng/ml) at a single time point (1 h) is also
shown (compare lanes 10 and 11, respectively, with lane 9). In
contrast to ECV304 cells, H2O2 failed to activate NF-kB in
HUVECs. No activation was apparent upon a 2- or 4-h incuba-
tion of HUVECs with either 0.2 or 0.4 mM H2O2 (compare lanes
12–15 with lane 9). Higher doses of H2O2 also failed to activate
NF-kB (not shown). These results highlight an important dif-
ference between the transformed (ECV304) and primary (HU-
VEC) ECs in terms of responsiveness of NF-kB to H2O2.
Cytokines and Hydrogen Peroxide Stimulate IkBa Degrada-
tion in ECV304 Cells, but with Different Kinetics—Since deg-
radation of the inhibitory subunit IkBa is a common key event
in the activation of NF-kB by diverse stimuli, the effect of IL-1,
TNF, and H2O2 on IkBa levels in ECV304 cells was examined.
Fig. 2 shows a marked difference in the kinetics of IL-1-, TNF-,
and H2O2-stimulated IkBa degradation. Although there was a
large decrease in IkBa levels in response to IL-1 by 20 min
(compare lanes 2 and 1) and to TNF by 1 h (compare lanes 6 and
1), H2O2-stimulated degradation was only detectable at 2 h
(lane 10), and obvious by 3 h (lane 13). By 4 h, IkBa levels were
NF-kB Activation in Endothelial Cells 25943
 at M
aynooth U
niversity on June 17, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
increasing again in the case of IL-1 and TNF (lanes 14 and 15),
whereas levels were still decreasing in response to H2O2 (lane
16). This slower degradation of IkBa induced by H2O2 in com-
parison with IL-1 and TNF was consistent with the different
time course of NF-kB activation for the cytokines and H2O2
described above.
Hydrogen Peroxide Levels Do Not Increase in Response to
IL-1, TNF, or PMA in ECV304 Cells—We next determined the
effect of IL-1, TNF, and PMA on H2O2 production by ECV304
cells. The rate of H2O2 production over 30 min was measured.
Table I shows that there was no significant increase above
basal H2O2 release from ECV304 cells upon exposure to IL-1,
TNF, or PMA over five separate experiments. This suggested
that an increase in intracellular H2O2 levels is not necessary
for IL-1, TNF, or PMA activation of NF-kB in ECV304 cells.
PDTC Differentially Inhibits NF-kB Activated by IL-1, TNF,
and PMA in ECV304 Cells and HUVECs—PDTC has been
shown to inhibit NF-kB activated by a variety of agents in
different cell types. We therefore tested the effect of this inhib-
itor on NF-kB activation in both ECV304 cells and HUVECs.
Surprisingly, PDTC failed to inhibit NF-kB binding activity
stimulated by IL-1 in ECV304 cells. Fig. 3A shows that the
FIG. 1. Kinetics of the effect of IL-1, TNF, PMA, and H2O2 on NF-kB activation in ECV304 cells and HUVECs. Confluent monolayers
of ECV304 cells (A, B, and C) or HUVECs (D) were treated as follows before preparation of nuclear extracts. A, ECV304 cells were treated with
vehicle (Co), 10 ng/ml IL-1, 10 ng/ml TNF, 100 ng/ml PMA, or 0.2 mM H2O2 for the times indicated above the lanes. B, nuclear extracts from ECV304
cells stimulated for 1 h with IL-1, TNF, or PMA or for 4 h with H2O2 were incubated with 18 or 180 fmol of unlabeled wild type or mutant NF-kB
probe as indicated for competition analysis (described under “Experimental Procedures”). C, nuclear extracts from ECV304 cells stimulated for 1 h
with IL-1, TNF, or PMA or for 4 h with H2O2 were incubated with antisera to p50, RelA, or c-Rel as indicated for supershift analysis (described
under “Experimental Procedures”). The position of supershifted complexes is indicated with an upper (RelA) and lower (p50) arrowhead. D,
HUVECs were treated with vehicle (Co), 10 ng/ml IL-1 for the stated times, or 10 ng/ml TNF or 100 ng/ml PMA for 1 h. In lanes 12–15, cells were
treated with 0.2 or 0.4 mM H2O2 for 2 or 4 h as indicated. Control (Co) levels of NF-kB remained unchanged at different time points in all
experiments. In all cases, nuclear extracts were assessed for the presence of NF-kB as described under “Experimental Procedures.” In A and D,
lanes 1–8, retarded protein-DNA complexes are shown by a filled arrowhead, and unbound DNA probe is shown by an open arrowhead.
Subsequently, only retarded NF-kBzDNA complexes are shown. Results shown are representative of 2–4 experiments.
FIG. 2. IL-1, TNF, and H2O2 stimulate IkBa degradation in ECV304 cells but with different kinetics. Confluent ECV304 monolayers
were stimulated with 10 ng/ml IL-1, 10 ng/ml TNF, or 0.2 mM H2O2 for the indicated times. Control cells were left untreated (Con) and remained
unchanged over the time course of the experiment. Cell lysates were prepared and assessed for the presence of IkBa by Western blotting as
described under “Experimental Procedures.” The band marked with an arrow was the only one detected and corresponds to IkBa. The positions
of the relevant molecular weight markers are shown. Results are representative of two experiments.
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IL-1-stimulated activity was completely insensitive to a range
of PDTC concentrations (lanes 2–6). Interestingly, TNF and
PMA were inhibited. Pretreatment of cells for 1 h with 0.01–10
mM PDTC caused a dose-dependent inhibition of the NF-kB
binding activity stimulated by TNF or PMA (compare lanes
8–11 with lane 7 and lanes 13–16 with lane 12). This inhibition
was partially relieved at 10 mM PDTC in the case of PMA (lane
16). Activation of NF-kB by H2O2 in ECV304 cells was also
inhibited by PDTC (compare lanes 18 and 17).
A different result was obtained in HUVECs, however. Both
IL-1- and TNF-activated NF-kB were completely insensitive to
PDTC. 0.01–10 mM PDTC had no effect on IL-1 activation (Fig.
3B, compare lanes 3–6 with lane 2) as was the case for ECV304
cells, while in contrast to ECV304s, 0.1–10 mM PDTC also
failed to inhibit TNF (compare lanes 8–12 with lane 7). Acti-
vation of NF-kB by PMA in HUVECs was potently inhibited by
PDTC, however (compare lanes 15–18 with lane 14), demon-
strating that the compound was active in these cells and that at
least one pathway to NF-kB in HUVECs was still sensitive to
PDTC.
Hence, in endothelial cells, only some pathways to NF-kB
were sensitive to PDTC, depending on the particular stimu-
lants used and on whether the cells were primary (HUVECs) or
transformed (ECV304s).
Inhibition of NF-kB by PDTC in ECV304 Cells Is Due to the
Compound’s Dithiocarboxy Group—To elucidate the mecha-
nism of inhibition of PDTC, studies were carried out involving
structural and functional analogues. Fig. 4A shows that an-
other dithiocarbamate, diethyldithiocarbamate (DDTC) mim-
icked the pattern of inhibition seen for PDTC in ECV304 cells
in that, over the concentration range 0.01–10 mM, IL-1 activa-
tion of NF-kB proved insensitive to DDTC (compare lanes 3–6
with lane 2), whereas both TNF- and PMA-activated NF-kB
were inhibited (compare lanes 8–11 with lane 7 and lanes
13–16 with lane 12). Similar to PDTC, inhibition was partially
relieved at 10 mM DDTC for PMA (lane 16). Two other com-
pounds with similar structures to PDTC, but lacking the di-
thiocarboxy group, PGA, and pyrrolidine, failed to inhibit ei-
ther TNF or PMA activation of NF-kB at 1 mM (Fig. 4, B and C),
a concentration at which PDTC and DDTC were inhibitory.
Fig. 4D shows the structures of PDTC, DDTC, PGA, and pyr-
rolidine for comparison. These results indicated that the inhib-
itory activity of PDTC was due to its dithiocarboxy group.
Effect of Other Antioxidants and Iron Chelators on NF-kB
Activation by IL-1, TNF, and PMA in Endothelial Cells—We
next examined structurally unrelated, functional analogues of
PDTC. Dithiocarbamates are known to have antioxidant (9)
and iron-chelating properties (20). We therefore tested the
effect of other antioxidants on NF-kB activation by IL-1, TNF,
and PMA. The radical scavenger and glutathione precursor
NAC has been shown to inhibit NF-kB in some cell types (12,
13) but not others (16, 17). Fig. 5, A and B, show that NAC
failed to inhibit the IL-1-, TNF-, or PMA-stimulated pathways
to NF-kB in either ECV304 cells or HUVECs. Pretreatment of
either endothelial cell type for 1 h with 10–40 mM NAC had no
effect on NF-kB activated by IL-1, TNF, or PMA. However,
NAC was found to inhibit activation of NF-kB by H2O2 in
ECV304 cells (Fig. 5A, compare lanes 14 and 13), highlighting
a further difference between this pathway to NF-kB activation
and the cytokine-mediated pathways. NAC also inhibited acti-
vation of NF-kB by TNF in Jurkat T cells within the same
concentration range (Fig. 5C, compare lanes 3–5 with lane 2),
as has been previously reported (12), pointing to a difference
between TNF responses in Jurkat cells and ECs.
Another antioxidant, the xanthine oxidase inhibitor allopuri-
nol (tested up to 1 mM), also failed to inhibit NF-kB activated by
IL-1, TNF, and PMA in ECV304 cells (not shown).
We next tested iron chelators. ECV304 cells were pretreated
with the specific ferric iron chelator DFO for 18 h (the longer
preincubation time was necessary, since DFO is taken up
slowly by mammalian cells (33)) before a 1-h stimulation with
IL-1, TNF, or PMA. Fig. 6 shows that activation of NF-kB by
both TNF and PMA was dose-dependently inhibited between
0.1 and 1 mM DFO (compare lanes 6–9 with lane 5, and com-
pare lanes 12–15 with lane 11), while concentrations of up to 1
FIG. 3. Effect of PDTC on NF-kB ac-
tivation by IL-1, TNF, PMA, and H2O2
in ECV304 cells and HUVECs. Conflu-
ent monolayers of ECV304 cells (panel A)
or HUVECs (panel B) were pretreated for
1 h with 0, 0.01, 0.1, 1, or 10 mM PDTC, as
indicated. Cells were subsequently stim-
ulated as follows before preparation of nu-
clear extracts. Panel A, ECV304 cells
were treated with vehicle (C), 10 ng/ml
IL-1, 10 ng/ml TNF, or 100 ng/ml PMA for
1 h or with 0.2 mM H2O2 for 4 h. Panel B,
HUVECs were treated with vehicle (C),
10 ng/ml IL-1, 10 ng/ml TNF, or 100 ng/ml
PMA for 1 h. In all cases, nuclear extracts
were assessed for the presence of NF-kB
as described under “Experimental Proce-
dures.” Retarded protein-DNA complexes
are shown. Results are representative of
two or three experiments.
TABLE I
IL-1, TNF, and PMA do not increase extracellular H2O2 release in
ECV304 cells
Confluent monolayers of ECV304 cells were left untreated (control) or
stimulated with the indicated concentration of IL-1, TNF, or PMA for 30
min. H2O2 release from the cells was measured as described under
“Experimental Procedures.” The data are expressed as the mean 6S.E.
for five experiments, each performed in triplicate. There was no signif-
icant difference between values for stimulated and control cells.
Treatment H2O2 release
pmol/min/mg protein
Control 6.7 6 1.6
10 ng/ml IL-1 6.6 6 1.4
10 ng/ml TNF 7.6 6 1.7
100 ng/ml PMA 8.2 6 2.3
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mM DFO had no effect on IL-1 activation (compare lanes 3 and
4 with lane 2). The inhibitory effect of DFO was confirmed to be
due to its iron-chelating properties, since co-incubation of DFO
with an equimolar concentration of ferric ions prevented its
inhibitory effect on NF-kB activation by TNF (compare lanes 10
and 8).
Another compound with activity toward metals mimicked
the pattern of PDTC and DFO inhibition in ECV304 cells,
namely TEMPO, a nitroxide spin trap that can maintain iron
as Fe31 and thus prevent redox cycling of the transition metal
(34). Fig. 7A shows that, similar to PDTC and DFO, IL-1-
activated NF-kB was insensitive to 1–2 mM TEMPO (compare
lanes 3 and 4 with lane 2), while both TNF- and PMA-activated
NF-kB proved sensitive to the compound over this concentra-
tion range (compare lanes 6 and 7 with lane 5, and compare
lanes 9 and 10 with lane 8, respectively). In addition, DMPO,
another commonly used spin trap that does not have such
activity against iron but can trap hydroxyl and superoxide
radicals (35), had no effect on IL-1-, TNF-, or PMA-stimulated
NF-kB activation up to 40 mM (Fig. 7B).
These results suggested that the basis of the PDTC inhibi-
tion is iron chelation rather than a general antioxidant effect
and that the TNF pathway in ECV304 cells has a requirement
for iron that is able to redox cycle.
PDTC and DFO Inhibit NF-kB Activation by Preventing
IkBa Degradation—The effect of the inhibitors on IL-1-, TNF-,
and H2O2-stimulated IkBa degradation was determined.
ECV304 cells were pretreated with 0.5 mM PDTC for 1 h or 0.5
mM DFO for 18 h before stimulation with IL-1 or TNF for 1 h or
H2O2 for 4 h, as was the case for measurement of NF-kB
activation in the inhibitor studies above. Fig. 8 shows that
PDTC or DFO had no effect on IL-1-mediated IkBa degradation
(compare lanes 3 and 4 with lane 2), as would be expected from
the lack of effect of these compounds on IL-1-mediated NF-kB
activation. In contrast, both PDTC and DFO strongly inhibited
TNF-stimulated IkBa degradation (compare lanes 6 and 7 with
lane 5), consistent with their effect on TNF-mediated NF-kB
activation. These results confirm the different sensitivities of
the IL-1 and TNF pathways to PDTC and DFO in ECV304 cells
and also suggest that PDTC was inhibiting NF-kB activation in
ECs by preventing IkBa degradation. PDTC also strongly in-
hibited degradation of IkBa induced by a 4-h treatment with
H2O2 (compare lanes 9 and 8).
TNF, but Not IL-1 or H2O2, Increases Lipid Peroxidation in
ECV304 Cells—DFO, DDTC, and TEMPO have well docu-
mented inhibitory effects on lipid peroxidation (33, 36, 37).
Since lipid peroxidation has been implicated in NF-kB activa-
tion in some systems (14, 38–40), we therefore determined
whether this was important for the difference between IL-1 and
TNF here. Lipid peroxidation was assessed by the TBARS
assay, which detects mainly MDA, an end product of the per-
oxidation of polyunsaturated fatty acids and related esters.
This method has been shown to be a sensitive index of lipid
peroxidation (41–43).
FIG. 4. PDTC inhibition of NF-kB activation is due to its di-
thiocarbamate moiety. Confluent ECV304 monolayers were pre-
treated with the indicated concentrations of DDTC (panel A), PGA
(panel B), or pyrrolidine (panel C) before stimulation with 10 ng/ml
IL-1, 10 ng/ml TNF, or 100 ng/ml PMA for 1 h as indicated. Control cells
were left unstimulated, indicated by C above the lanes. Nuclear extracts
were prepared and assessed for the presence of NF-kB as described
under “Experimental Procedures.” Retarded protein-DNA complexes
are shown. Results are representative of two experiments. In panel D,
the structure of the compounds is shown for comparative purposes.
FIG. 5. Effect of N-acetyl-L-cysteine on NF-kB activation in
ECV304 cells, HUVECs, and Jurkat T cells. Cells were pretreated
with 0, 10, 20, or 40 mM NAC for 1 h as indicated and were subsequently
stimulated as follows. Panel A, ECV304 cells were treated with 10 ng/ml
IL-1, 10 ng/ml TNF, or 100 ng/ml PMA for 1 h or with 0.2 mM H2O2 for
4 h. Panel B, HUVECs were treated with 10 ng/ml IL-1, 10 ng/ml TNF,
or 100 ng/ml PMA for 1 h. Panel C, Jurkat T cells were treated with 10
ng/ml TNF for 1 h. Control cells were left unstimulated (C, first lane of
each panel). Nuclear extracts were prepared and assessed for the pres-
ence of NF-kB as described under “Experimental Procedures.” Retarded
protein-DNA complexes are shown. Results are representative of two or
three experiments.
FIG. 6. Desferrioxamine mimics the pattern of NF-kB inhibi-
tion seen for PDTC in ECV304 cells. Confluent monolayers of
ECV304 cells were pretreated for 18 h with the indicated concentrations
of DFO (0, 0.1, 0.3, 0.5, and 1 mM) before stimulation for 1 h with 10
ng/ml IL-1, 10 ng/ml TNF, or 100 ng/ml PMA. In lane 10, 0.5 mM FeCl3
was added to cells at the same time as DFO. Control cells were left
unstimulated (Co). Nuclear extracts were prepared and assessed for the
presence of NF-kB as described under “Experimental Procedures.” Re-
tarded protein-DNA complexes are shown. Results are representative of
four experiments.
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Table II (top) shows that treatment of ECV304 cells with
TNF for 30 min (which strongly activates NF-kB) did indeed
increase lipid peroxidation. Levels of TBARS showed a small
but highly significant increase of 123 6 2% (p , 0.01) above
control levels. The magnitude of the effect is consistent with a
noncytotoxic increase in lipid peroxidation. Importantly, stim-
ulation of cells with IL-1 for 30 min failed to increase TBARS
above control values. Interestingly, treatment of cells with
H2O2 for 4 h also did not increase TBARS, suggesting that
ECV304 cells have very effective antioxidant defense mecha-
nisms and that lipid peroxidation is unlikely to have a role in
H2O2-mediated NF-kB activation in these cells. In total, 19
separate experiments were performed using TNF, some of
which involved PDTC, DFO, or BHA as inhibitors (see below).
TNF was also used as a positive control in separate experi-
ments involving IL-1 and H2O2.
PDTC and DFO both inhibited lipid peroxidation in the cells.
Table II (middle and bottom) shows experiments for DFO and
PDTC, respectively. DFO decreased basal levels of TBARS to
59 6 5% of control values. PDTC was less potent, decreasing
levels to 82 6 17%. Both compounds were able to effectively
block the TNF-mediated increase in TBARS, since when cells
were preincubated with DFO and PDTC before stimulation
with TNF, TBARS values recorded were similar to those seen
for the compounds alone.
These results pointed to iron-catalyzed lipid peroxidation as
the basis for the differential sensitivity of TNF and IL-1 to
PDTC and DFO.
Effects of t-BHP and BHA on NF-kB and TBARS—We next
examined whether a compound used to increase lipid peroxi-
dation within cells, t-BHP, can itself activate NF-kB. Fig. 9A
shows that treatment of ECV304 cells for 4 h with 0.2–1.0 mM
t-BHP led to a dose-dependent activation of NF-kB. We con-
firmed that t-BHP was increasing lipid peroxidation within the
cells, since, although it only gave a slight reaction itself with
TBA, in the presence of cells TBARS levels increased to 149 6
6% of control levels (n 5 6). Thus, activation of NF-kB is
possible by simply increasing lipid peroxidation.
Finally, we explored the potential role of lipid peroxidation in
the TNF but not the IL-1 pathway by testing BHA, a chain-
breaking antioxidant that inhibits lipid peroxidation but has no
iron-chelating properties. Fig. 9B shows that pretreatment of
cells with 0.2 mM BHA for 2 h strongly inhibited TNF-stimu-
lated NF-kB activation (compare lanes 3 and 2). In contrast,
IL-1-stimulated activation was totally insensitive to this pre-
treatment (compare lanes 5 and 4). We also confirmed that
BHA, like PDTC and DFO, could indeed inhibit lipid peroxida-
tion and block the TNF-mediated increase in TBARS (Table
FIG. 7. TEMPO mimics the pattern of NF-kB inhibition seen
for PDTC in ECV304 cells, while DMPO has no effect. Confluent
monolayers of ECV304 cells were pretreated for 2 h with the indicated
concentrations of TEMPO (A) (0, 1, and 2 mM) or DMPO (B) (0, 10 and
40 mM) before stimulation for 1 h with 10 ng/ml IL-1, 10 ng/ml TNF, or
100 ng/ml PMA. Control cells were left unstimulated (Co). Nuclear
extracts were prepared and assessed for the presence of NF-kB as
described under “Experimental Procedures.” Retarded protein-DNA
complexes are shown. Results in A are representative of three experi-
ments, while those in B are representative of two experiments.
FIG. 8. Effect of PDTC and desferrioxamine on IL-1-, TNF-, and
H2O2-induced IkBa degradation in ECV304 cells. Confluent
ECV304 monolayers were pretreated with 0.5 mM PDTC for 1 h or 0.5
mM DFO for 18 h as indicated before stimulation with vehicle control
(Con), 10 ng/ml IL-1, or 10 ng/ml TNF for 1 h or with 0.2 mM H2O2 for
4 h. Cell lysates were prepared and assessed for the presence of IkBa by
Western blotting as described under “Experimental Procedures.” The
band marked with an arrow was the only one detected and corresponds
to IkBa. The position of the relevant molecular weight markers is
shown. Results are representative of three experiments.
TABLE II
Effect of NF-kB activators and inhibitors on TBARS formation in
ECV304 cells
Top, confluent monolayers of ECV304 cells were stimulated with 40
ng/ml IL-1 or TNF for 30 min or 0.4 mM H2O2 for 4 h. Middle, cells were
pretreated for 18 h with 0.5 mM DFO before stimulation with or without
TNF. Bottom, cells were pretreated for 1 h with 0.5 mM PDTC before
stimulation with or without TNF. In all cases, TBARS levels were
measured in triplicate as described under “Experimental Procedures,”
and results were calculated as nmol of MDA equivalents/mg of protein.
Results shown are mean 6 S.E. TBARS levels are expressed as a
percentage of matched controls (untreated cells). The number of exper-
iments is indicated in parentheses. The mean 6 S.E. control value
over 26 experiments was 0.25 6 0.02 nmol of MDA equivalents/mg of
protein.
Treatment
TBARS
(percentage of
control)
Effect of IL-1, TNF, and H2O2 on TBARS
%
IL-1 102 6 4 (6)
TNF 123 6 2 (19)a
H2O2 97 6 7 (4)
Effect of DFO on basal and TNF-stimulated TBARS
%
DFO 59 6 5 (3)a
TNF 117 6 2 (3)a
TNF 1 DFO 50 6 3 (3)a,b
Effect of PDTC on basal and TNF-stimulated TBARS
%
PDTC 82 6 17 (2)
TNF 115 6 2 (3)a
PDTC 1 TNF 84 6 3 (3)a,b
a p , 0.05 versus control.
b p , 0.05 versus TNF.
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III). These results provide strong evidence that lipid peroxida-
tion is a necessary part of the signal activated by TNF that
leads to NF-kB activation.
Taken together, the data indicate that activation of NF-kB
by TNF but not IL-1 involves increases in iron-catalyzed lipid
peroxidation.
DISCUSSION
In this study, we have investigated the role of H2O2 as well
as the effect of a range of antioxidants on IL-1- and TNF-
stimulated NF-kB activation in both primary and transformed
human ECs. We first investigated the particular role played by
H2O2 as a signal for NF-kB activation. We found that H2O2
release from ECV304 was not increased upon stimulation with
IL-1, TNF, or PMA, as measured at concentrations and times of
exposure to stimulants that gave strong activation of NF-kB in
these cells. This is consistent with a study by Royall et al. (44)
in bovine aortic endothelial cells, where they showed that TNF
had no effect on intra- or extracellular H2O2 levels over a period
of 12 h. Adding H2O2 to ECV304, however, activated NF-kB
and induced IkBa degradation. Both responses were signifi-
cantly slower than those seen for the cytokines. In addition, the
peroxide-mediated activation proved sensitive to the antioxi-
dant NAC, unlike that mediated by cytokines. These differ-
ences called into question the relevance of H2O2 in cytokine
activation of NF-kB in ECs. Similar slow kinetics for NF-kB
activation by H2O2 and other signals that induce oxidative
stress have been reported by other groups in lymphoid cells
(45–47). This may be characteristic of a response of NF-kB to
agents that induce oxidative stress.
The failure of H2O2 to activate NF-kB in HUVECs was in
agreement with the findings of Bradley et al. (15). It is difficult
to discern why H2O2 activated NF-kB in the transformed and
not the primary ECs. It has been known for some time that
transformed cells have lower levels of antioxidant enzymes and
subsequently a higher cellular oxidative potential than pri-
mary cells (48), implying that transformed cells would be more
susceptible to the effects of H2O2. Chiao et al. (49) recently
demonstrated that primary rat embryo fibroblasts were resist-
ant to H2O2-induced apoptosis, while their adenovirus-trans-
formed counterparts were sensitive. Sen et al. (50) have shown
that differences in the kinetics of an increase in intracellular
[Ca21] in response to H2O2 may be the basis of the difference in
sensitivity of NF-kB to H2O2 in sensitive and insensitive Jur-
kat subclones, which could conceivably be important in the
primary-transformed difference observed in our study. Inter-
estingly, they also treated cells for 4 h, with 0.25 mM H2O2,
similar to the conditions used here.
Our experiments with PDTC revealed for the first time a
receptor-mediated, PDTC-insensitive pathway to NF-kB (acti-
vated by IL-1) in the same cell type (ECV304) as a receptor-
mediated pathway that is sensitive (activated by TNF). It has
been reported recently that the activation of NF-kB by IL-1 in
epithelial cell lines is also insensitive to PDTC (47). We also
found a difference in sensitivity between a particular pathway
(TNF) in a transformed and primary cell line. This implies that
PDTC inhibition of NF-kB is neither stimulus- nor cell type-
independent as has been previously postulated (9). Different
TNF responses between primary and transformed cells have
been reported by others. For example, TNF is cytotoxic to many
tumor cells but not primary cells (51).
The pathway activated by PMA was sensitive to PDTC in
both cell types. This was an important control, demonstrating
that PDTC was active in the primary cells. It also indicated
that the PMA response consistently activated NF-kB in a
PDTC-sensitive manner, irrespective of whether the cells were
primary or transformed, presumably through a protein kinase
C-dependent pathway.
PDTC could have a number of effects within cells, including
scavenging of ROS (9), chelation of divalent metal ions (20),
alteration of intracellular thiol levels (52), and modification of
proteins by decomposition products (53). The comparison with
structural and functional analogues of PDTC demonstrated
that its inhibitory effect on TNF was probably due to metal
chelation rather than a general antioxidant effect. The failure
of the widely used antioxidant NAC to inhibit the cytokines
while inhibiting H2O2 was further evidence against a role for
oxidative stress in NF-kB activation by the cytokines. We and
others have shown insensitivity to NAC in response to IL-1
and/or TNF in other cell types (16, 17, 47). We were unable to
find a single report of NAC inhibiting NF-kB in ECs. Like
PDTC, an effect of NAC on gene expression has often been used
to implicate NF-kB in that pathway, but it has been shown that
both compounds can inhibit protein expression independent of
an effect on NF-kB (17, 54, 55).
Because of the lack of effect of NAC, it was possible that the
metal-chelating properties of PDTC were responsible for its
inhibitory effect, as distinct from its antioxidant properties. We
therefore examined two metal chelators, DFO and TEMPO.
FIG. 9. Effect of t-BHP and BHA on NF-kB in ECV304 cells. A,
confluent ECV304 monolayers were treated with 0.2, 0.4, or 1.0 mM
t-BHP for 4 h. Control cells were left untreated (Co). Nuclear extracts
were prepared and assessed for the presence of NF-kB as described
under “Experimental Procedures.” Retarded protein-DNA complexes
are shown. The band marked with an arrow corresponds to a p50/Rel A
heterodimer (see Fig. 1C). Results are representative of four experi-
ments. B, confluent monolayers of ECV304 cells were pretreated for 2 h
with 0.2 mM BHA (lanes 3 and 5) before stimulation for 1 h with or
without 10 ng/ml TNF or IL-1. Control cells were left unstimulated (Co).
Nuclear extracts were prepared and assessed for the presence of NF-kB
as described under “Experimental Procedures.” Retarded protein-DNA
complexes are shown. Results are representative of three experiments.
TABLE III
Effect of BHA on basal and TNF-stimulated TBARS
Confluent monolayers of ECV304 cells were pretreated with 0.2 mM
BHA for 2 h before stimulation with or without 40 ng/ml TNF for 30
min. Control cells were left untreated. TBARS levels were measured in
triplicate as described under “Experimental Procedures,” and results
were calculated as nmol of MDA equivalents/mg of protein. Results
shown are mean 6 S.E. TBARS levels are expressed as a percentage of
control. The number of experiments is indicated in parentheses.
Treatment TBARS (percentage of control)
%
BHA 74 6 4 (3)a
TNF 121 6 6 (4)a
TNF 1 BHA 84 6 2 (4)a,b
a p , 0.02 versus control.
b p , 0.02 versus TNF.
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Both of these mimicked the pattern of inhibition of NF-kB by
PDTC in ECV304 cells. DFO is a specific ferric iron chelator
(33). The addition of ferric ions prevented the inhibition of the
TNF-mediated activation, indicating that DFO was inhibiting
via its iron-chelating properties. This is the first report of
TEMPO inhibiting NF-kB activation. In addition to scavenging
superoxide anion and hydroxyl radical, this nitroxide spin trap
compound can maintain iron in its ferric form and thus prevent
it from redox cycling (34, 56). Since the other ROS scavengers
NAC and DMPO did not inhibit activation of NF-kB by TNF, it
is likely that TEMPO was inhibiting due to its ability to trap
iron in its ferric form. This ability of TEMPO to chelate iron is
a key difference between it and DMPO. Taken together, these
results suggest that the property of PDTC (and DDTC) that is
important in its inhibitory effect on NF-kB in ECs is its ability
to chelate iron. Both PDTC and DDTC have high affinities for
iron, with log b3 values for ferrous ions of 12.7 and 11.3,
respectively (57).
PDTC and DFO were found to block TNF-stimulated IkBa
degradation. Since degradation of IkBa is tightly coupled to its
phosphorylation and subsequent release from the latent com-
plex, PDTC was likely to be inhibiting the TNF (and PMA)
pathway(s) at a point upstream of IkBa phosphorylation. Thus,
inhibition by PDTC in ECV304 cells defines a requirement of
the TNF, but not the IL-1 pathway to NF-kB for iron, at a point
upstream of IkBa phosphorylation.
We suspected that the role of iron in TNF-mediated NF-kB
activation in ECV304 cells was to promote lipid peroxidation
and that the failure of PDTC and DFO to inhibit NF-kB acti-
vation by IL-1 was due to the lack of involvement of lipid
peroxidation in the IL-1 pathway. Inhibition by DFO and
TEMPO suggested that the iron required was available to these
compounds and that redox cycling of iron was necessary for
NF-kB activation by TNF. This could suggest an involvement of
the Fenton reaction, but this was felt to be unlikely since we
found no role for H2O2 in any of the pathways to NF-kB in these
cells. The lack of effect of NAC and DMPO on the pathways
would also argue against this. However, iron-dependent lipid
peroxidation could be important, since this process requires
redox cycling of iron and does not necessarily require H2O2 or
ROS (58). Indeed, iron has a key role in both the initiation and
propagation of lipid peroxidation, leading to the generation of
peroxyl and alkoxyl radicals as well as lipid peroxides (58). A
role for iron-catalyzed lipid peroxidation was further suggested
by the fact that DDTC, DFO, and TEMPO all have well docu-
mented inhibitory effects on iron-catalyzed membrane lipid
peroxidation (33, 36, 37). In addition, there are a number of
reports in the literature implicating lipid peroxidation in path-
ways to NF-kB. TNF-stimulated NF-kB binding activity was
inhibited by lipid peroxide inhibitors such as BHA and aneth-
oldithiolthione in T cell lines (14, 38). The addition of linoleic
acid to porcine pulmonary endothelial cells led to an increase in
lipid peroxide levels and activation of NF-kB, both responses
being inhibited by pretreatment of cells with the lipid peroxide
scavenger vitamin E (39). There is also strong evidence that
NF-kB mediates the induction of inflammatory genes known to
be activated by lipid-peroxide species, such as those generated
in vivo by oxidized low density lipoprotein (5, 40, 59).
In this study, several lines of evidence implicated iron-cata-
lyzed lipid peroxidation in TNF- but not IL-1-mediated NF-kB
activation in transformed ECs. First, stimulation of ECV304
cells with TNF led to an increase in TBARS, with no effect
observed with IL-1. Second, PDTC and DFO limited lipid per-
oxidation in the cells, as indicated by a decrease in TBARS, and
further blocked the TNF-mediated increase in TBARS. Third,
t-BHP, an agent well known to increase lipid peroxidation,
activated NF-kB. Finally and most importantly, similar to DFO
and PDTC, a nonchelating inhibitor of lipid peroxidation, BHA,
also inhibited lipid peroxidation and TNF- but not IL-1-stimu-
lated NF-kB activation. Particular lipid peroxides or radicals,
generated via an iron-dependent mechanism, are therefore
likely to have a key role in mediating NF-kB activation by TNF
in ECV304 cells. The fact that t-BHP gave a larger increase of
TBARS than TNF while being a weaker activator of NF-kB
may suggest that lipid peroxidation is necessary but not suffi-
cient for the TNF pathway. t-BHP may give rise to a different
subset of lipid peroxides that may include only low levels of the
putative lipid peroxides required by TNF. This would be con-
sistent with the low levels of NF-kB in control cells despite
detectable levels of TBARS. The precise mechanism whereby
TNF induces lipid peroxidation in an iron-dependent manner
remains to be determined. TNF could stimulate the release of
iron from a heme protein or from the mitochondrial redox
chain. Alternatively, 5-lipoxygenase may be involved, since this
enzyme requires DFO-chelatable, redox-active iron and leads
to the generation of lipid peroxides (60). Interestingly, this
enzyme has been implicated in TNF-mediated cytotoxicity (61)
and also in NF-kB activation by CD28 in primary T cells (11).
As neither IL-1 nor H2O2 increased lipid peroxidation and
yet activated NF-kB, other processes can clearly activate
NF-kB in ECs. The inhibitory effect of PDTC on H2O2 was most
likely due to the antioxidant properties of PDTC.
Other differences are beginning to emerge between TNF and
IL-1 signaling pathways, particularly with regard to early com-
ponents involved in NF-kB activation. TRAF-2 has been shown
to be critical for NF-kB activation by TNF but not IL-1 (62),
while TRAF-6 has been implicated in NF-kB activation by IL-1
alone (63). A common kinase for both cytokine pathways has
been identified, however, termed NF-kB-inducing kinase,
which lies downstream of TRAF-2 and possibly of TRAF-6 (64).
We speculate that lipid peroxidation occurs on the TRAF-2
pathway upstream of NF-kB-inducing kinase.
A role for lipid peroxidation in the activation of NF-kB in ECs
may have wider implications. Several groups have suggested
and provided evidence that activated NF-kB has a role in the
pathogenesis of atherosclerosis and that activation may be
mediated by lipid peroxides released from oxidized low density
lipoprotein, since this molecule is atherogenic and can activate
NF-kB (5, 24, 40, 59). Coupled with the fact that activated
NF-kB has recently been identified in endothelial cells in the
atherosclerotic lesion (4), it will be important to fully investi-
gate the role of lipid peroxides in NF-kB activation in ECs.
In conclusion, this study argues against a role for H2O2 or
ROS in NF-kB activation by IL-1 or TNF in ECs. However, the
mechanisms by which TNF and IL-1 activate NF-kB differ,
with the TNF pathway in ECV304 cells involving iron-cata-
lyzed lipid peroxidation.
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